Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient

HER2 amplification/overexpression is a common driver in a variety of cancers including gallbladder cancer (GBC). For patients with metastatic GBC, chemotherapy remains the standard of care with limited efficacy. The combination of HER2 antibody trastuzumab plus chemotherapy is the frontline treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Li, Li, Xiaomo, Cheng, Yurong, Yang, Jing, Liu, Si, Ma, Tonghui, Luo, Li, Hu, Yanping, Cai, Yi, Yan, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770537/
https://www.ncbi.nlm.nih.gov/pubmed/35069555
http://dx.doi.org/10.3389/fimmu.2021.784861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770537/
https://www.ncbi.nlm.nih.gov/pubmed/35069555
http://dx.doi.org/10.3389/fimmu.2021.784861

Ejemplares similares